Grantmaking Process

The following is a condensed description of CCCF’s grantmaking process. A more detailed description is available upon request.

  

1.      The Foundation will accept various kinds of contributions from individuals and organizations.

  

2.      Contributions may be co-mingled and divided into allotments of $2,000 to $5,000 for distribution as seed grants to initiate and support basic science and translational cancer research.

  

3.      CCCF will contact cancer research and treatment centers and related organizations to identify planned or ongoing research.

 

4.      CCCF will identify research programs suited to funding by the Foundation and will thoroughly review submitted research proposals

  

5.      Upon review of the proposal, the Foundation and its medical advisors will determine whether a proposed research project shall be funded.

  

6.      Following acceptance of a proposal, CCCF will distribute the grant money and establish a timetable for feedback on the progress of the work.

  

7.      CCCF will monitor the progress of the funded project at least annually. Grant recipients must provide annual written progress reports.

  

8.      At the end of the calendar year, the Foundation will determine whether or not funding of the project will continue.

 

9.      The process outlined above is anticipated to take place simultaneously for several research projects that may be ongoing or occurring over the same time period. CCCF’s initial goal is to provide an annual budget for research funding of $5,000 to $20,000 per calendar year.

  

This grantmaking process has been employed very successfully over the past five years in funding cancer research projects by The Patricia L. Knebel Memorial Fund. Many contributions have already been made to medical technology by utilizing this process.



3D rendered DNA molecule with black nucleotides representing cancer mutation
3D rendered DNA molecule with black
nucleotides representing cancer mutation.
Therapeutic DNA spills from a traditional drug capsule. It's a matter of innovative research and time.
Therapeutic DNA spills from a traditional drug capsule.
It's a matter of innovative research and time.